Viseon closed a USD $18 million Series B financing. Proceeds will support ongoing product development, worldwide regulatory approvals, clinical evaluations, manufacturing scale-up and commercialization.
The company is in limited commercial use of Viseon visualization and illumination technology for minimally invasive spine surgery procedures to positive early surgeon response. Viseon continues to collect clinical feedback and utility in the U.S. and is assessing international commercialization opportunities; full launch is slated for 2H20.
Jeffrey Valko, President and CEO, said, “We are very pleased to have the ongoing support from our current investment partners, with confidence underscored by inside-only investor participation and oversubscription. Ongoing advancements in minimally invasive surgical techniques often bring the consequence, and risk of limited visualization. As fundamental as it may seem, enhanced real-time intraoperative visualization projected onto a large high-definition flat panel display will contribute toward clinical outcomes improvement, procedural efficiency, reduced risk of complications, OR staff involvement teaching opportunity and procedure expansion.”
Viseon technologies can be adapted for a wide range of cervical, thoracic and lumbar procedures. The disposable products can reduce the burdens of high capital equipment cost, O.R. footprint, maintenance and calibration expense, OR scheduling, reusable sterilization risks, procedural inefficiencies and user ergonomic burdens.